dtx

By Dave Muoio 11:47 am October 30, 2019
Pear Therapeutics has announced a new deal with Ironwood Pharmaceuticals that will explore the platform’s potential for patients with certain gastrointestinal (GI) conditions. “We are excited to be partnering with Ironwood on this initiative and believe there is a compelling clinical rationale for use of [prescription digital therapeutics] in treating GI diseases,” Dr. Corey McCann, president and...
By Dave Muoio 10:28 am October 16, 2019
Editor's Note: This story has been updated with additional quotes from Pear Therapeutics. The poster child of digital therapeutics-pharma collaborations is soon to be no more, as Novartis division Sandoz announced that it is handing sole responsibility for the commercialization of the reSET and reSET-O prescription digital therapeutics back to Pear Therapeutics. “Pear and Sandoz previously signed...

Photo credit: Rock Health 

By Laura Lovett 11:51 am October 15, 2019
A decade ago digital health was a relatively new term, largely without name recognition. Today, the venture dollars tell a new story, with $8.1 billion poured into the space in 2018 alone, according to a Rock Health report. Still, most healthcare stakeholders agree digital health is still in its early days and is grappling with questions about its place in the health ecosystem.  Founded in 2010,...
By Dave Muoio and Laura Lovett 03:45 pm September 27, 2019
It’s been two years since the first software-only digital therapeutic got the FDA greenlight, but the industry is still very much in its infancy and continuing to evolve. New entrances are emerging from the world of health, pharma, tech and finance. As the industry matures, it's grappling with existential questions including regulation, reimbursement models and, as always, the definition of a...
By Dave Muoio 03:12 pm June 12, 2019
Yesterday, CVS Health unveiled Vendor Benefit Management, a new service that will help CVS Caremark pharmacy benefit management (PBM) clients roll out and manage third-party health products. As the service is applicable to both digital and non-digital health and wellness products, the company has decided to inaugurate its initiative by announcing Big Health — maker of the CBT-based sleep app...
By Dave Muoio 03:48 pm May 21, 2019
Minneapolis-based NightWare — maker of a smartwatch therapeutic for people with nightmare disorder and PTSD-driven nightmares — has received breakthrough therapy designation for its in-development product. In addition, the company is launching two new placebo-controlled randomized clinical trials for its digital intervention, one of which is being conducted within Department of Veterans Affairs...
By Dave Muoio 02:32 pm May 16, 2019
Express Scripts will be releasing a stand-alone formulary in 2020 that highlights vetted digital health tools for the pharmacy benefit management firm’s payer and consumer customers, according to an announcement released this morning. The company said that it will be treating the new formulary in much the same way it would a similar resource for traditional medications. To be included, a digital...
By Joe Slavinsky 01:58 pm May 16, 2019
About the author: Joe Slavinsky leads business development efforts with pharmaceutical, biotechnology and medical technology companies in his VP position at Propeller Health. A former epidemiologist, he worked at a hedge fund (Citadel) and an investment bank (Thomas Weisel Partners) as an equity research analyst covering small/mid-cap biotechnology companies. Joe joined Propeller from Gilead...
By Dave Muoio 01:13 pm May 6, 2019
Editor's Note: An original headline for this story contained an error, and has since been corrected. Boston- and San Francisco-based Pear Therapeutics, maker of prescription digital therapeutics for substance abuse, has kicked off a feasibility study for Pear-006, an in-development treatment for depressive symptoms in those with multiple sclerosis (MS). Pear Therapeutics has been developing Pear-...
By Dave Muoio 03:14 pm April 9, 2019
Although still in its earliest chapters, the story of digital therapeutics is beginning to pick up steam. Just six months ago, that the first software-only therapeutic cleared by the FDA, Pear Therapeutics’ reSET, kicked off a commercial launch driven by the sales channels expertise of an established pharmaceutical partner. Proteus, meanwhile, recently expanded dealings with its long-time pharma...